Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Colorcon
Dow
McKesson

Last Updated: May 26, 2022

Investigational Drug Information for Dalcetrapib


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Dalcetrapib?

Dalcetrapib is an investigational drug.

There have been 15 clinical trials for Dalcetrapib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.

The most common disease conditions in clinical trials are Myocardial Ischemia, Heart Diseases, and Coronary Disease. The leading clinical trial sponsors are Hoffmann-La Roche, The Montreal Health Innovations Coordinating Center (MHICC), and DalCor Pharmaceuticals.

There are seven hundred and twenty-eight US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Dalcetrapib
TitleSponsorPhase
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19CovancePhase 2
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19The Montreal Health Innovations Coordinating Center (MHICC)Phase 2
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19DalCor PharmaceuticalsPhase 2

See all Dalcetrapib clinical trials

Clinical Trial Summary for Dalcetrapib

Top disease conditions for Dalcetrapib
Top clinical trial sponsors for Dalcetrapib

See all Dalcetrapib clinical trials

US Patents for Dalcetrapib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dalcetrapib See Plans and Pricing IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE) See Plans and Pricing
Dalcetrapib See Plans and Pricing Combination therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) See Plans and Pricing
Dalcetrapib See Plans and Pricing Compounds useful for the treatment of metabolic disorders and synthesis of the same North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC) See Plans and Pricing
Dalcetrapib See Plans and Pricing Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
Dalcetrapib See Plans and Pricing Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein Merck Sharp & Dohme Corp. (Rahway, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dalcetrapib

Drugname Country Document Number Estimated Expiration Related US Patent
Dalcetrapib Australia AU2011326871 2030-11-08 See Plans and Pricing
Dalcetrapib Brazil BR112013010157 2030-11-08 See Plans and Pricing
Dalcetrapib Canada CA2815749 2030-11-08 See Plans and Pricing
Dalcetrapib China CN103260625 2030-11-08 See Plans and Pricing
Dalcetrapib China CN105288580 2030-11-08 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Colorcon
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.